Putative human liver progenitor cells in explanted liver.

BACKGROUND/AIMS: Hepatocyte progenitors have frequently been cultured from rodents but reports from human liver are rare. METHODS: Non-parenchymal cell fraction isolated from 19 explant livers (removed at orthotopic liver transplantation for acute or chronic liver disease) and histologically normal human liver was cultured. RESULTS: Proliferating epithelioid colonies were identifiable after 2-3 weeks culture as a very rare event (<1 per million cells plated) expressing mRNAs and protein antigens of mixed hepatocytic/biliary phenotype. Colony survival could be prolonged by transduction of the catalytic sub-unit of telomerase. Hepatocyte growth factor, epidermal growth factor and oncostatin M did not further enhance hepatocytic differentiation. The expression of markers associated with hepatocyte precursor status was investigated by flow cytometry. Cells expressing the stem cell-associated markers CD133 and CD117 were identified at low frequency. The proportion of cells expressing the integrin CD49f was higher in diseased liver than in normal liver, but the proportion expressing the hepatocyte growth factor receptor c-met was lower. Successful enrichment of plated populations for progenitors was not achieved. CONCLUSION: Although there is clear histological evidence of hepatocyte precursors in human explant livers, predictable culture of such cells with differentiation toward mature hepatocyte phenotype remains elusive.

Medical devices; hematology and pathology devices; classification of cord blood processing system and storage container. Final rule.

The Food and Drug Administration (FDA) is classifying a cord blood processing system and storage container into class II (special controls). The special control that will apply to this device is the guidance document entitled "Class II Special Controls Guidance Document: Cord Blood Processing System and Storage Container." FDA is classifying this device into class II (special controls) in order to provide a reasonable assurance of safety and effectiveness of this device. Elsewhere in this issue of the Federal Register, FDA is announcing the availability of the guidance document that will serve as the special control for this device.

High-speed cell sorting: fundamentals and recent advances.

Cell sorters have undergone dramatic technological improvements in recent years. Driven by the increased ability to differentiate between cell types, modern advances have yielded a new generation of cytometers, known as high-speed cell sorters. These instruments are capable of higher throughput than traditional sorters and can distinguish subtler differences between particles by measuring and processing more optical parameters in parallel. These advances have expanded their use to facilitate genomic and proteomic discovery, and as vehicles for many emerging cell-based therapies. High-speed cell sorting is becoming established as an essential research tool across a broad range of scientific fields and is poised to play a pivotal role in the latest therapeutic modalities.

Myoepithelial cells: pathology, cell separation and markers of myoepithelial differentiation.

Until recently the myoepithelial cell has been studied relatively little in terms of its role in breast cancer. A number of malignancies showing myoepithelial differentiation have been reported in the literature, although they are still thought to be relatively rare and only limited studies are published. As a result of recent expression profiling experiments, one type of tumor with myoepithelial features, the so-called 'basal' breast cancer, has received a renewed interest, although it has been known to pathologists for more than two decades. These tumors, which express markers of both luminal and myoepithelial cells, are now being studied using antibodies against some new molecules that have emerged from studies of sorted normal luminal and myoepithelial cells. These immunohistochemical data, combined with genomic studies, may lead to better identification and management of patients with 'basal' tumors.

Primera experiencia en aislamiento de celulas endoteliales humans en Bolivia / First experience in the isolation of human endothelian cells in Bolivia

INTRODUCCIÓN: las células endoteliales pueden proveer información valiosa con respecto a muchos procesos patológicos como la aterosclerosis, inflamación, neoplasia y angiogénesis. Este trabajo describe la primera experiencia boliviana en el aislamiento y cultivo de células endoteliales humanas derivadas de la vena umbilical (HUVEC). MÉTODOS: Un segmento largo de cordón umbilical se utilizó para el aislamiento y fue tratado por digestión con colagenasa. Las células endoteliales fueron desprendidas de la íntima y posteriormente cultivadas en medio de cultivo M199 y suero fetal bovino. Técnicas morfológicas, inmunohistoquímicas y de citometría de flujo fueron utilizadas para identificar estas células. RESULTADOS: Se examinaron las células endoteliales obtenidas por análisis morfológico e inmunohistoquímico. El marcaje con CD34 fue positivo para más del 90% de las células obtenidas por digestión con colagenasa analizado por citometría de flujo. CONCLUSIÓN Se logró aislar y cultivar HUVEC de manera exitosa. Una gran variedad de experimentos y aplicaciones en ciencias biomédicas pueden ser potencialmente factibles.

INTRODUCTION: endothelial cell study yields valuable information concerning many pathologic processes such as atherosclerosis, inflammation, neoplasia and angiogenesis. This paper describes the first Bolivian experience in isolation and culture of human umbilical vein endothelial cells (HUVEC). METHODS: a long segment of the umbilical cord was processed by collagenase digestion. Endothelial cells were detached from intima and further cultured using M199 culture media. Morphologic, immunochemistry and flow cytometry approaches were used to identify these cells. RESULTS: morphologic and immunochemistry analysis of the pool of obtained cells were positive for HUVEC. CD34 staining was positive in more than 90% of the cells obtained by collagenase digestion as assessed by flow cytometry. CONCLUSION: HUVEC were successfully isolated for the first time in Bolivia. A great deal of further experiments and applications in biomedical sciences is possible